var data={"title":"Lidocaine and tetracaine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lidocaine and tetracaine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/57621?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lidocaine-and-tetracaine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lidocaine and tetracaine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=lidocaine-and-tetracaine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lidocaine and tetracaine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181967\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pliaglis [DSC];</li>\n      <li>Synera</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181970\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Topical;</li>\n      <li>\n        Local Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181995\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Anesthesia, topical: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Cream:</i> Superficial dermatological procedures: Prior to procedure, apply to intact skin for 20 to 60 minutes. Amount of cream varies depending on size of the surface area to be treated; see manufacturer&rsquo;s labeling for detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Patch: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Venipuncture or intravenous cannulation: Prior to procedure, apply to intact skin for 20 to 30 minutes; <b>Note:</b> May use another patch at a new location to facilitate venous access after a failed attempt; remove previous patch.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Superficial dermatological procedures: Prior to procedure, apply to intact skin for 30 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181994\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=lidocaine-and-tetracaine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lidocaine and tetracaine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Anesthesia, topical: </b>Children &ge;3 years and Adolescents: Patch: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1623501\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24744767\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Lidocaine primarily undergoes hepatic metabolism and its pharmacokinetics are not expected to be changed significantly following topical administration of recommended doses in renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181996\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use caution in patients with severe hepatic dysfunction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1182001\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, external:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pliaglis: Lidocaine 7% and tetracaine 7% (30 g [DSC], 100 g [DSC]) [contains methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Lidocaine 7% and tetracaine 7% (30 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch, transdermal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Synera: Lidocaine 70 mg and tetracaine 70 mg (10s) [contains heating component, metal; each patch is ~50 cm<sup>2</sup>]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3362805\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: cream</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181997\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical cream: Apply to intact, healthy skin. Spread self-occluding cream evenly and thinly (approximately 1 mm) across the treatment area using a flat-surfaced tool (eg, metal spatula, tongue depressor). After waiting the required application time, remove the cream by grasping a free-edge with fingers and pulling it away from the skin. Alternatively, the cream may be removed with gauze. If skin irritation or a burning sensation occurs, remove cream. Wash hands after handling cream. Carefully discard the used cream out of the reach of children and pets. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch: Apply to intact, healthy skin. Use immediately after opening pouch. Patch begins to heat once removed from pouch. May increase skin temperature by 5&deg;C, will not exceed 40&deg;C. If irritation or burning sensation occurs during application, remove patch. Wash hands after applying. Do not cut the patch or remove the top cover. Do not cover the holes on the top side of the patch. Carefully dispose of used patches as they contain large amounts of lidocaine and tetracaine. Fold adhesive together following use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181971\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Anesthesia, topical: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream: For use on intact skin in adults to provide topical local analgesia for superficial dermatological procedures, including dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch: For use on intact skin in patients &ge; 3 years to provide local analgesia for superficial venous access and superficial dermatological procedures, including excision, electrodessication, and shave biopsy of skin lesions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11394984\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch may contain conducting metal (eg, iron); remove patch prior to MRI.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181978\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Also see individual agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Dermatologic: Erythema (47% to 71%), localized blanching (12% to 16%), skin edema (12% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&le;1%), drowsiness (&le;1%), headache (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Application site dermatitis (&lt;4%), application site rash (&lt;4%), local discoloration (&lt;4%), acne vulgaris (&le;1%), ecchymosis (&le;1%), maculopapular rash (&le;1%), xeroderma (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;1%), vomiting (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Petechial rash (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, angioedema, apprehension, blepharitis, bronchospasm, burning sensation of skin, confusion, convulsions, dehydration, diaphoresis, fever, hypersensitivity reaction, hyperventilation, infection, pain, pallor, paresthesia, pharyngitis, pruritus, respiratory depression, skin blister, stupor, syncope, tremor, urticaria, vesiculobullous dermatitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181974\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to lidocaine, tetracaine, amide or ester-type anesthetic agents, para-aminobenzoic acid (PABA), or any other component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181975\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Methemoglobinemia: Has been reported with local anesthetics including tetracaine. Use caution in patients with congenital or idiopathic methemoglobinemia, children &lt;12 months of age, concurrent use with methemoglobin-inducing medications, or in those patients with glucose-6-phosphate dehydrogenase deficiencies</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Other local anesthetics: If being used with other products containing local anesthetic, consider potential for additive effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acutely ill patients: Use with caution in acutely ill patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Debilitated patients: Use with caution in debilitated patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pseudocholinesterase deficiency: Use with caution in patients with pseudocholinesterase deficiency; greater risk of lidocaine/tetracaine toxicity. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Topical cream: Application of cream for longer duration than recommended, or application over larger surface areas is not recommended because of the risk for increased drug absorption and possible adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Transdermal patch: Application of patch for longer duration than recommended, or simultaneous or sequential application of multiple patches is not recommended because of the risk for increased drug absorption and possible adverse reactions. Patch may contain conducting metal (eg, iron); remove patch prior to MRI. Proper storage and disposal of used patches are essential to prevent accidental exposures, especially in children; accidental exposure may result in serious adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Avoid contact with eye; loss of protective reflexes may predispose to corneal irritation and/or abrasion. Application to broken or inflamed skin or mucous membranes may lead to increased systemic absorption. Not for use at home.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181984\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181983\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10241&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiarrhythmic Agents (Class III): Lidocaine (Topical) may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May increase the serum concentration of Lidocaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: May enhance the arrhythmogenic effect of Lidocaine (Topical). Disopyramide may increase the serum concentration of Lidocaine (Topical). Specifically, the unbound/free fraction of lidocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methemoglobinemia Associated Agents: Tetracaine (Topical) may enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181972\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181973\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have not been observed in animal reproduction studies with this combination. Systemic absorption following topical application is expected to be low. Systemic absorption would be required in order for lidocaine and tetracaine to cross the placenta and reach the fetus. Refer to Lidocaine (Systemic), Lidocaine (Topical), and Tetracaine (Systemic) monographs. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7827425\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Lidocaine is excreted in breast milk; it is not known if tetracaine is excreted in breast milk. Systemic absorption following topical application is expected to be low; according to the manufacturer, the small amount ingested by a nursing infant would not be expected to cause adverse events.  The manufacturer recommends that caution be exercised if administered to nursing women. Refer to Lidocaine (Systemic), Lidocaine (Topical), and Tetracaine (Systemic) monographs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181999\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">Effectiveness of anesthesia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181988\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\"> Local anesthetic action occurs by stabilization of neuronal membranes and inhibiting the sodium ion fluxes required for the initiation and conduction of impulses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1181990\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Also see individual agents.</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Onset: Within 20 to 30 minutes</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Duration: Cream: 11 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Related to duration of application and area where applied. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Lidocaine crosses the blood-brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>: Lidocaine: Neonates: 2.75 L/kg; Adults: 1.1 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Lidocaine: 70%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lidocaine: Metabolized in the liver by cytochrome P450 CYP1A2 and partially by CYP3A4 to inactive and active metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tetracaine: Hydrolysis by plasma esterases to primary metabolites para-aminobenzoic acid and diethylaminoethanol  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Lidocaine: Adults: 1.8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Lidocaine: Excreted in urine as metabolites and parent drug </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321913\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Lidocaine-Tetracaine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7-7% (30 g): $293.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (Synera External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70-70 mg (1): $19.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038861\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anestic Cream (BD);</li>\n      <li>Pliaglis (AR, AT, BE, BR, CH, DE, ES, FR, GB, HK, IE, NL, PL, PT, SG);</li>\n      <li>Pliapel (DK, NO);</li>\n      <li>Ralydan (DK, IT);</li>\n      <li>Rapydan (AT, BE, GR, LU, NL, NO, PL, PT, SE);</li>\n      <li>Rapyden (CZ);</li>\n      <li>Telica (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Pliaglis (lidocaine and tetracaine) [prescribing information]. Hawthorne, NY: TaroPharma; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synera (lidocaine and tetracaine) [prescribing information]. Souderton, PA: Galen US Inc; March 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10241 Version 137.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F1181967\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F1181970\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F1181995\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1181994\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F1623501\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F24744767\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F1181996\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F1182001\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F3362805\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1181997\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1181971\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F11394984\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F1181978\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F1181974\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F1181975\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F1181984\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F1181983\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F1181972\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1181973\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F7827425\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1181999\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F1181988\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F1181990\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321913\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038861\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10241|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lidocaine-and-tetracaine-patient-drug-information\" class=\"drug drug_patient\">Lidocaine and tetracaine: Patient drug information</a></li><li><a href=\"topic.htm?path=lidocaine-and-tetracaine-pediatric-drug-information\" class=\"drug drug_pediatric\">Lidocaine and tetracaine: Pediatric drug information</a></li></ul></div></div>","javascript":null}